Yangjing Capsule Can Improve the Function of the Testicular Angiogenesis through Activating VEGFA/eNOS Signaling Pathway

Baofang Jin,†,1 Dalin Sun,1 Weihang Dong,2 Bing Chen,3 Weimin Deng,1 Bin Cai,1 Yugui Cui,4 Yihan Jin,2 Jianguo Liu,3 Li Tong,2 and Ping Wu2

1Andrology Department of Integrative Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China
2Medical College, Qinghai University, Xi’ning 810001, China
3Department of Andrology, Yuncheng Hospital of Traditional Chinese Medicine, Yuncheng 044000, China
4State Key Laboratory of Reproductive Medicine, Clinical Center of Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
5Department of Andrology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an 710003, China

Correspondence should be addressed to Baofang Jin; hexiking@126.com and Jianguo Liu; kukulushui123@163.com

Received 19 December 2019; Revised 16 March 2020; Accepted 24 March 2020; Published 25 April 2020

Guest Editor: Rômulo Dias Novaes

Copyright © 2020 Baofang Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The testicular microcirculation was an important aspect of testicular physiology and it offered a stable environment for the transport of nutrients and secretary products in the testis. Yangjing capsule (YC), a traditional Chinese compound herbal prescription, has been proved as an effective drug to ameliorate spermatogenesis, promote testosterone synthesis in vivo, and cure spermatogenesis in clinical practice. Objective. This study was aimed at understanding the potential mechanisms of YC exerting angiogenic effects in the mouse spermatogenesis dysfunction model induced by cyclophosphamide (CP) and MLTC-1 cells. Materials and Methods. Balb/c mice were randomly divided into five groups: control, CP, CP plus YC (630 mg/kg), CP plus YC (1260 mg/kg), and CP plus YC (2520 mg/kg). After 30 days, mice were sacrificed and the expressions of endothelial marker CD34+, angiogenic marker VEGFA, VEGFR1, VEGFR2, and eNOS in the testes of the mice were examined; moreover, Leydig cell line MLTC-1 cells were cultured and treated with different concentrations of YC extracts (YCE), and the expressions of VEGFA, VEGFR1, VEGFR2, and eNOS, as well as the secretion of NO, were evaluated. Results. We observed that YC significantly increased the expressions of VEGFA, VEGFR1, VEGFR2, and eNOS in testes of CP-treated mice; moreover, YCE has led to increased expressions of VEGFA, VEGFR1, VEGFR2, and eNOS and secretion of NO in MLTC-1 in vitro. These data suggested that the YC might be an alternative treatment for the dysfunction of testicular microcirculation by promoting the angiogenesis in the testis.

1. Introduction

The testicular microcirculation was an important aspect of testicular physiology. Functionally, it offered stable environment for transport of nutrients and secretary products in the testis [1, 2]. Angiogenesis represents the formation of new vessels from existing vasculature. It is necessary to have adequate and appropriate amount of angiogenesis in testis. Either impaired or excessive angiogenesis was associated with the abnormal pathophysiologic alterations of the testis which can further lead to abnormalities in microcirculation and impaired the testicular functions such as spermatogenesis and hormonal and paracrine control [3, 4].

The vascular endothelial growth factor (VEGF) is a well-known angiogenic factor [5]. It was regarded as important candidates for the regulation of physiological and pathophysiologic angiogenesis [6]. The VEGF was also an endothelium-specific secreted protein that potently stimulated vasodilation and microvascular hyperpermeability [7, 8]. Among the angiogenic factors, VEGF is a multifunctional...
protein, and it played a key role in new blood vessel formation. Previously, it had been shown that a member of the VEGF family, vascular endothelial growth factor A (VEGFA) was a powerful mitogen for human dermal microvascular endothelial cells that expressed both VEGFR1 and VEGFR2 in vitro [9]. In addition, VEGFA could stimulate the endothelial cell of microvessels to proliferate, migrate, and change their gene expression pattern [10]. More and more research studies had proved the important role of VEGFA in microcirculation [11, 12].

The Yangjing capsule (YC) is a traditional Chinese compound herbal preparation. It consisted of Herba Epimedi Brevicornus, Rhizoma Polygonati Sibirici, Placenta Hominis, Radix Rehmanniae Preparata, Angelica Sinensis, and other components [13]. YC had been used to treat male infertility and sexual dysfunction for many years in China. A previous study suggested that YC could enhance sperm motility and testosterone synthesis for infertile men [14]. Another study reported that YC could ameliorate spermatogenesis in male mice induced by CP; hence, YC may be an efficient drug to improve spermatogenesis in patient [13]. Some components in YC were considered to regulate angiogenesis in vitro and in vivo. For instance, Angelica Sinensis exerted antiangiogenesis effects in human umbilical vein endothelial cells [15]. Steroidogenesis acute regulatory protein (StAR), another component in YC, was considered to be involved in Leydig cell angiogenesis [16]. However, the effects of YC on the angiogenesis in testis remain unclear.

In this study, we performed in vivo analysis to explore the roles of YC in regulating the angiogenesis in the testis of cyclophosphamide- (CP-) induced mouse spermatogenesis dysfunction model, and we also determined the effect of YC on Leydig cell line MLTC-1 cells in vitro. Our data may provide novel evidence for the use of YC as an alternative method to improve the function of the testicular microcirculation by promoting the angiogenesis in the testis.

2. Materials and Methods

2.1. Chemicals and Drugs. The PrimeScript RT Master Mix and SYBR Green PCR Master Mix reagent kits were purchased from TaKaRa (TaKaRa Biotechnology, Dalian, China). The primers were synthesized by Invitrogen Life Tech (Carlsbad, CA, USA). The protein assay kit was obtained from Beyotime (Beyotime Institute of Biotechnology, Shanghai, China). The cyclophosphamide was purchased from Pude Medicine Co. Ltd. (Nanjing, China). The RPMI 1640 medium and fetal bovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA).

2.2. Preparation of the YC. The YC was obtained from Nanjing General Hospital of Nanjing Military Region (Nanjing, China). It was composed of 11 traditional Chinese drugs: Radix Rehmanniae Preparata, Semen Astragali Complanati, Herba Epimedi Brevicornus, Mongolica, Placenta Hominis, Radix Angelicae Sinensis, Hirudo, Rhizoma Polygonati Sibirici, Radix Astragali, Semen Litchi, Semen Vaccariae Segetalis, and Concha Ostreae (calcined). The YC extract was acquired according to the methods described previously [17].

2.3. Animals and Treatments. The mature male (8- to 10-week-old) Balb/c mice (25 ± 2 g) were purchased from Nanjing University (Nanjing, China). Mice were fed with standard food and water ad libitum under standard laboratory conditions. After adapting to the environment for a week, the mice were randomly divided into five groups (10 mice/group): control, CP, CP plus YC (630 mg/kg), CP plus YC (1260 mg/kg), and CP plus YC (2520 mg/kg). For the first 7 days, the mice of CP and YC groups were injected with CP once a day since the first day of the experiment. After 30 days, the mice in the YC treatment groups were administered with YC suspension via gavage once a day. The general health of the animals was assessed daily. Finally, the fresh testis frozen in liquid nitrogen was used for the isolation of RNA and extraction of proteins. This study has been approved by the Animal Ethics Committee of Southeast University.

2.4. Immunohistochemistry. On day 30, mice were sacrificed, and the testes were collected, fixed with formalin, embedded with paraffin, and sectioned into 6–8 μm slices. To examine the presence of CD34 in different samples, the sections were treated with the citrate buffer at 100°C for 1 h and then incubated with the anti-CD34 antibodies (ab81289, 1:100, Abcam, Cambridge, USA) at 4°C overnight. The following day, the sections were incubated with the secondary antibodies for 1 h and incubated with streptavidin-horseradish peroxidase (SA10001, 1:100, Thermo Fisher Scientific Inc., USA) for 30 min at room temperature. Finally, the sections were stained with diaminobenzidine (DAB), and the images were visualized by microscopy.

2.5. Cell Culture. MLTC-1 cells were obtained from the Cell Institute of Shanghai (Shanghai, China). MLTC-1 cells were cultured in RPMI-1640 containing 10% fetal bovine serum in 5% CO₂ at 37°C. According to a previous study, the cells were treated with 0, 0.01, 0.1, and 1 mg/mL YC extract (YCE) and incubated for up to 24 h in a humidified atmosphere of 5% CO₂ at 37°C [13].

2.6. RNA Extraction and qRT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. The qRT-PCR assays were performed to detect the expressions of VEGFA, VEGFR1, and VEGFR2 using the PrimeScript RT reagent Kit and SYBR Premix Ex Taq (TaKaRa, Dalian, China) according to the manufacturer’s instruction. The PCR primers were designed as follows: VEGFA sense 5'-GCAGGGCTGAGGTGTA-3' and VEGFA reverse 5'-CTACCCGATTTTTCTGACCTCT-3', VEGFR1 primer sense 5'-GGTATCCCTCAACCTACA-3' and VEGFR1 primer reverse 5'-CCACAGTCCCACTTTATT-3', VEGFR2 primer sense 5'-ACTGTCATCCTTAC-3' and VEGFR2 primer reverse 5'-
cycles of 95 °C for 30 s and 59 °C for 35 s and 60 °C for 30 s in the ABI 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). We used the 2^{-ΔΔCt} method to calculate the relative abundance of the target mRNAs. GAPDH has been applied as the internal control.

2.7. Western Blot Analysis. The total proteins isolated from testes of the mice and the MLTC-1 cells were obtained following the standard procedures and quantified by using the bicinchoninic acid protein assay (Beyotime, Shanghai, China). The proteins were separated by 12% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore) and incubated with the rabbit anti-VEGFA (ab46154, 1:1000, Abcam, Cambridge, USA), rabbit anti-VEGFR1 (ab32152, 1:100, Abcam, Cambridge, USA), rabbit anti-VEGFR2 (ab5473, 1:100, Abcam, Cambridge, USA), rabbit anti-eNOS (ab5589, 1:100, Abcam, Cambridge, USA), and rabbit anti-GAPDH (ab9485, 1:2500, Abcam, Cambridge, USA) overnight at 4 °C. On day 2, after washing with PBS three times, the membranes were incubated with goat anti-rabbit HRP-conjugated secondary antibodies (ab6721, 1:5000, Abcam, Cambridge, USA) at 37 °C for 1 h. The relative protein levels in each sample were normalized to the levels of GAPDH to standardize the variations.

2.8. Determination of the Content of NO. The content of NO in the cell culture supernatant was determined by a commercially available kit (purchased from Beyotime, Shanghai, China) according to the manufacturer’s instructions.

2.9. Statistical Analysis. Each cell experiment was repeated three times, and all data are represented as mean ± standard deviation (SD). Analysis of variance (ANOVA) has been applied for the comparisons among multiple groups. P values less than 0.05 were considered statistically significant.

3. Results

3.1. The Effect of YC on the Expression of CD34 in Mice Testes. First, we examined the effect of the YC on the angiogenesis in mice testes by comparing the expression of CD34 in different groups using IHC and WB methods. As shown in Figure 1(a), the density of blood vessels was significantly decreased in the CP group and the structure of testicular vasculature was severely damaged, compared with the control group; after YC treatment, the density of blood vessels was increased and the structure damage was partially reversed in a concentration-dependent manner (P < 0.01); on the other hand, YC treatment induced presence in the expression of CD34 in mice testes (Figure 1(b), P < 0.05) compared with the CP group, and the angiogenic effect of 2520 mg/kg YC was more significant (P < 0.01).

3.2. The Effect of YC on the Expressions of VEGFA, VEGFR1, and VEGFR2 in Mice Testes. Moreover, the levels of angiogenic factors VEGFA, VEGFR1, and VEGFR2 in the testes of mice with different treatments were also evaluated. It was observed that CP induced marked decrease in the expressions of VEGFA, VEGFR1, and VEGFR2 compared with the control group, and different concentrations of YC treatment increased the expressions of VEGFA, VEGFR1, and VEGFR2 compared with the model group (Figure 2).

3.3. The Effect of YC on the Expression Level of eNOS in Mice Testes. eNOS has been known as a downstream enzyme of VEGF. Next, to further examine the angiogenic effects of YC in mice testes, we analyzed the expression profiles of eNOS in the testes of mice with different treatments. As shown in Figure 3, CP has led to decreased expression of eNOS in testes of mice, while on the other hand, 630 mg/kg and 1260 mg/kg YC induced a significant increase in the expression of eNOS in testes of the CP-treated mice (P < 0.05); moreover, 2520 mg/kg YC had no significant effect on the expression of eNOS in testes of CP-treated rats.

3.4. The Effect of YCE on the Expressions of VEGFA, VEGFR1, and VEGFR2 in MLTC-1 Cells. To further explore the underlying mechanism of YC-induced angiogenic effects, the MLTC-1 cells were cultured and treated with different concentrations (0.01, 0.1, and 1 mg/mL) of YC extracts (YCE), and the expressions of VEGFA, VEGFR1, and VEGFR2 were examined by quantitative real-time PCR and WB methods. We observed that 0.1 and 1 mg/mL YCE significantly increased the mRNA expression of VEGFA, VEGFR1, and VEGFR2 in a dose-dependent manner (Figure 4); moreover, results of WB analysis revealed that 0.1 and 1 mg/mL YCE markedly increased the protein expressions of VEGFA, VEGFR1, and VEGFR2 in a dose-dependent manner (Figure 5). On the other hand, 0.01 mg/mL YCE had no significant effects on the expressions of VEGFA, VEGFR1, and VEGFR2 in MLTC-1 cells.

3.5. The Effect of YCE on the Secretion of NO and Expression of eNOS in MLTC-1 Cells. Finally, the secretion of NO and expression of eNOS in MLTC-1 cells of different treatments were also evaluated. As shown in Figure 6, 0.1 and 1 mg/mL YCE significantly increased the secretion of NO in the cell culture supernatant of MLTC-1 cells in a dose-dependent manner (Figure 6(a)); furthermore, 0.1 and 1 mg/mL YCE also lead to increased expressions of eNOS in a dose-dependent manner (P < 0.05). On the other hand, 0.01 mg/mL YCE had no significant effects on the secretion of NO and expression of eNOS in MLTC-1 cells.

4. Discussion

In the present study, we found the density of blood vessels was significantly decreased and the structure of testicular vasculature was severely damaged when exposed to CP; meanwhile, the decrease and damage could be partially
reversed by adding YC in a concentration-dependent manner. Moreover, the presence of CD34 (an endothelial marker) was observed after YC treatment as well; moreover, we also observed that the extract of YC can increase the expression of VEGFA, VEGF receptors, and eNOS and increase the production of NO in Leydig cell line MLTC-1 cells. Our results suggested that YC may improve the angiogenesis in testis.

The protective roles of YC in male reproductive diseases have been discussed in several studies conducted by our research group. We previously reported that YC can increase the secretion of testosterone in MLTC-1 cells and may be a potential an alternative method for the treatment of insufficient testosterone relate diseases [13, 14]; moreover, YCE has been shown to activate the PI3K pathway and induced the self-renewal of the GC-1 spg cells [17, 18]; furthermore, in a very recent study, we observed that YC can inhibit the apoptosis of the MLTC-1 cells and via promoting the expression of STAR [16]. Meanwhile, in testis, the vasculature is of great importance because pituitary gonadotropins are delivered by testicular vasculature to support the process of spermatogenesis [19]; however, whether YC can promote testicular microcirculation or the angiogenesis in testis is still unclear. In the present study, we first observed
that CP treatment caused damage to the testicular vasculature, and on the other hand, YC protected the testicular vasculature in the testis of CP-treated spermatogenesis mice. Taken together, we proposed that YC may exert angiogenic effects in the testis of spermatogenesis dysfunction mouse, which may further lead to the regeneration of the testicular vasculature and alleviate the condition of spermatogenesis dysfunction.

Figure 2: The effects of YC on the expression of VEGFA, VEGFR1, and VEGFR2 in the testes of mice with different treatments. Data given are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. CP: cyclophosphamide; SD: standard deviation; YC: Yangjing capsule.

Figure 3: The effects of YC on the expression of eNOS in the testes of spermatogenesis dysfunction mice induced by CP. Data given are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. CP: cyclophosphamide; SD: standard deviation; YC: Yangjing capsule.

Figure 4: The effects of YCE on the mRNA expression of VEGFA, VEGFR1, and VEGFR2 in MLTC-1 cells. Data given are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. CP: cyclophosphamide; SD: standard deviation; YCE: Yangjing capsule extract.
Figure 5: The effects of YCE on the protein expressions of VEGFA, VEGFR1, and VEGFR2 in MLTC-1 cells. Data given are the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. CP: cyclophosphamide; SD: standard deviation; YCE: Yangjing capsule extract.

Figure 6: The effects of YCE on the secretion of NO and expression of eNOS in MLTC-1 cells. Data given are the mean ± SD. (a) Content of NO in the cell culture supernatant of different treatments; (b) expression of eNOS in different groups. *P < 0.05, **P < 0.01, ***P < 0.001. CP: cyclophosphamide; SD: standard deviation; YCE: Yangjing capsule extract.
VEGFA is a specific endothelium protein that potently stimulated angiogenesis, vasodilation, and microvascular hyperpermeability [11, 12, 20]. Functionally, it could alter its gene expression level to promote proliferation and migration for the endothelial cells. In testis, besides the angiogenic function, VEGFA can also stimulate the proliferation and testosterone secretion of Leydig cells [21]; moreover, VEGFA has been observed to regulate spermatogenesis via promoting the self-renewal, differentiation, and proliferation of the spermatogonial cells [22, 23]. In the current study, we observed that YC increased the expression of VEGFA and VEGF receptors in testes of CP-treated mice, suggesting that YC may promote angiogenesis in testis via regulating the expression of VEGFA; furthermore, Leydig cells secrete a number of growth factors, including VEGFA and VEGF receptors was also evaluated. Consistent with the in vivo observation, 0.1 and 1 mg/mL YCE induced increased expression of VEGFA and VEGFR on both mRNA and protein levels in Leydig cell line MLTC-1 cells in vitro. Taken together, these results suggested that YC can increase the expression of VEGF both in vitro and in vivo, which may induce its angiogenic function in testis.

Nitric oxide (NO) was a pleiotropic molecule critical to several physiological and pathological processes (reference). NO was synthesized from the amino acid L-arginine by either the constitutive endothelial NOS (eNOS) or the inducible NOS (iNOS) [26]. It has been reported in previous studies that VEGF can increase the expression of eNOS and secretion of NO [7, 8, 27, 28]. In the current study, we observed that 630 mg/kg and 1260 mg/kg YC significantly increased the expression of eNOS in testes of the CP-treated mice in vitro, and 0.1 and 1 mg/mL YCE also significantly increased the secretion of NO and the expressions of eNOS in MLTC-1 cells in vitro. Taken together, these results indicated that YC may activate the VEGFA/eNOS signaling pathway in testes of mice and MLTC-1 cells to exert its therapeutic effects.

5. Conclusion
In conclusion, we found that the Yangjing capsule may exert angiogenic effects in testes of mice spermatogenesis dys-function models and MLTC-1 cells via activating VEGFA/ eNOS signaling pathway. Our data suggested that Yangjing capsule may be an alternative medicine for the treatment of male infertility or hypogonadism diseases.

6. Additional Points
YC significantly increased the expressions of VEGFA, VEGFR1, VEGFR2, and eNOS in testes of CP-treated mice. YCE has led to increased expressions of VEGFA, VEGFR1, VEGFR2, and eNOS and secretion of NO in MLTC-1 in vitro. YC might be an alternative treatment for the dysfunction of testicular microcirculation by promoting the angiogenesis in the testis.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This work was supported by the Chinese National Natural Science Foundation (81774315, 81874472, 81473678, and 81603631).

References
[1] O. Collin, E. Lissbrant, and A. Bergh, “Atrial natriuretic peptide, brain natriuretic peptide and c-type natriuretic peptide: effects on testicular microcirculation and immunohistochemical localization,” International Journal of Andrology, vol. 20, no. 1, pp. 55–60, 1997.
[2] A. Bergh, E. Lissbrant, and O. Collin, “Temporal variations in testicular microcirculation,” Journal of Andrology, vol. 20, pp. 724–730, 1999.
[3] M. Gökhan-Küse, S. R. Erdem, Ç. L. Peşkiricioğlu, and B. Çaylak, “La inhibición de la angiogénesis deteriora la morfología testicular en modelo de rata con varicocele izquierdo experimental,” Actas Urológicas Españolas, vol. 38, no. 7, pp. 459–464, 2014.
[4] M. R. Goren, F. Kilinc, F. Kayaselcuk, C. Ozer, I. Oguzulgen, and E. Hasirci, “Effects of experimental left varicocelectomy on hypoxia-inducible factor-1alpha and vascular endothelial growth factor expressions and angiogenesis in rat testis,” Andrologia, vol. 49, no. 2, Article ID e12614, 2017.
[5] A. R. Albig and W. P. Schiemann, “Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells,” DNA and Cell Biology, vol. 23, no. 6, pp. 367–379, 2004.
[6] R. Fleischer, G. C. Weston, B. J. Vollenhoven, and P. A. W. Rogers, “Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation,” Best Practice & Research Clinical Obstetrics & Gynaecology, vol. 22, no. 4, pp. 603–614, 2008.
[7] H. Wang, L. Qiu, Y. Ma et al., “Naoxintong inhibits myocardial infarction injury by VEGF/eNOS signaling-mediated neovascularization,” Journal of Ethnopharmacology, vol. 209, pp. 13–23, 2017.
[8] Y. Liu, M. Paterson, S. L. Baumgardt et al., “Vascular endothelial growth factor regulation of endothelial nitric oxide synthase phosphorylation is involved in isoflurane cardiac preconditioning,” Cardiovascular Research, vol. 115, no. 1, pp. 168–178, 2019.
[9] S. Yano, H. Muguruma, Y. Matsumori et al., “Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice,” Clinical Cancer Research, vol. 11, no. 24, pp. 8789–8798, 2005.
[10] Z. Kasza, P. Fredlund Fuchs, C. Tamm et al., “MicroRNA-24 suppression ofN-deacetylase/N-Sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA),” Journal of Biological Chemistry, vol. 288, no. 36, pp. 25956–25963, 2013.
[11] R. R. Foster, L. Armstrong, S. Baker et al., “Glycosaminoglycan regulation by VEGFA and VEGFC of the glomerular microvascular endothelial cell glyocalyx in vitro,” *The American Journal of Pathology*, vol. 183, no. 2, pp. 604–616, 2013.

[12] A. L. Koenig, K. Baltrunaite, N. I. Bower et al., “Vegfa signaling promotes zebrafish intestinal vasculature development through endothelial cell migration from the posterior cardinal vein,” *Developmental Biology*, vol. 411, no. 1, pp. 115–127, 2016.

[13] H. Zhao, B. Jin, X. Zhang et al., “Yangjing capsule ameliorates spermatogenesis in male mice exposed to cyclophosphamide,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 980583, 8 pages, 2015.

[14] Y. Gu, X. Zhang, D. Sun et al., “The stimulative effect of Yangjing capsule on testosterone synthesis through Nur77 pathway in Leydig cells,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 408686, 8 pages, 2015.

[15] J.-C. Yeh, T. Cindrova-Davies, M. Belleri et al., “The natural compound n-butylidenephthalalide derived from the volatile oil of *Radix Angelica sinensis* inhibits angiogenesis in vitro and in vivo,” *Angiogenesis*, vol. 14, no. 2, pp. 187–197, 2011.

[16] D. Sun, W. Dong, B. Jin et al., “Mechanisms of Yangjing capsule in Leydig cell apoptosis and testosterone synthesis via promoting StAR expression,” *Biological and Pharmaceutical Bulletin*, vol. 41, no. 9, pp. 1401–1405, 2018.

[17] B. Jin, B. Cai, D. Sun et al., “Yangjing capsule extract promotes proliferation of GC-1 spg cells via up-regulated POU3F1 pathway,” *BioScience Trends*, vol. 11, no. 1, pp. 95–104, 2017.

[18] Z. Wang, B. Jin, X. Zhang, Y. Cui, D. Sun, and C. Gao, “Yangjing capsule extract promotes proliferation of GC-1 Spg cells,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 640857, 9 pages, 2014.

[19] D. Rebourcet, J. Wu, L. Cruickshanks et al., “Sertoli cells modulate testicular vascular network development, structure, and function to influence circulating testosterone concentrations in adult male mice,” *Endocrinology*, vol. 157, no. 6, pp. 2479–2488, 2016.

[20] X. Ma, Z. Li, T. Li, L. Zhu, Z. Li, and N. Tian, “Long non-coding RNA HOTAIR enhances angiogenesis by induction of VEGFA expression in glioma cells and transmission to endothelial cells via glioma cell derived-extracellular vesicles,” *American Journal of Translational Research*, vol. 9, pp. 5012–5021, 2017.

[21] K. M. Sargent, R. M. McFee, R. Spuri Gomes, and A. S. Cupp, “Vascular endothelial growth factor A: just one of multiple mechanisms for sex-specific vascular development within the testis?” *Journal of Endocrinology*, vol. 227, no. 2, pp. R31–R50, 2015.

[22] K. C. Caires, J. de Avila, and D. J. McLean, “Endocrine regulation of spermatogonial stem cells in the seminiferous epithelium of adult mice,” *BioResearch Open Access*, vol. 1, no. 5, pp. 222–230, 2012.

[23] K. M. Sargent, D. T. Clopton, N. Lu, W. E. Pohlmeier, and A. S. Cupp, “VEGFA splicing: divergent isoforms regulate spermatogonial stem cell maintenance,” *Cell and Tissue Research*, vol. 363, no. 1, pp. 31–45, 2016.

[24] H. Schwarzenbach, G. Chakrabarti, H. J. Paust, and A. K. Mukhopadhyay, “Gonadotropin-mediated regulation of the murine VEGF expression in MA-10 Leydig cells,” *Journal of Andrology*, vol. 25, no. 1, pp. 128–139, 2004.

[25] B. Dhole, S. Gupta, S. K. Venugopal, and A. Kumar, “Triiodothyronine stimulates VEGF expression and secretion via steroids and HIF-1alpha in murine Leydig cells,” *Systems Biology in Reproductive Medicine*, vol. 64, no. 3, pp. 191–201, 2018.

[26] J. Petrtyl, K. Dvorak, M. Jachymova et al., “Functional variants of eNOS and iNOS genes have no relationship to the portal hypertension in patients with liver cirrhosis,” *Scandinavian Journal of Gastroenterology*, vol. 48, no. 5, pp. 592–601, 2013.

[27] M. S. Islam, M. Matsumoto, R. Hidaka, N. Miyoshi, and N. Yasuda, “Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis,” *The Veterinary Journal*, vol. 192, no. 3, pp. 338–344, 2012.

[28] K. Engels, A. du Bois, P. Harter et al., “VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection,” *Journal of Clinical Pathology*, vol. 62, no. 5, pp. 448–454, 2009.